KOC
CRSP icon

Koss-Olinger Consulting’s CRISPR Therapeutics CRSP Stock Holding History

Koss-Olinger Consulting’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,447
Closed -$600K – 270
2025
Q4 		$600K Sell
11,447
-30,750
-73% -$1.84M 0.05% 145
2025
Q3 		$2.05M Hold
42,197
– – 0.17% 68
2025
Q2 		$2.05M Buy
42,197
+9,685
+30% +$375K 0.17% 68
2025
Q1 		$1.11M Sell
32,512
-1,656
-5% -$70.2K 0.09% 109
2024
Q4 		$1.34M Buy
34,168
+18,298
+115% +$864K 0.12% 84
2024
Q3 		$746K Sell
15,870
-48
-0.3% -$2.44K 0.06% 115
2024
Q2 		$860K Buy
+15,918
New +$921K 0.08% 108
2024
Q1 		– Sell
-29,962
Closed -$1.88M – 103
2023
Q4 		$1.88M Buy
29,962
+4,802
+19% +$265K 0.18% 58
2023
Q3 		$1.14M Buy
25,160
+3,660
+17% +$189K 0.17% 78
2023
Q2 		$1.21M Hold
21,500
– – 0.14% 78
2023
Q1 		$972K Buy
+21,500
New +$1.04M 0.12% 94
2021
Q3 		– Sell
-12,650
Closed -$2.05M – 246
2021
Q2 		$2.05M Buy
12,650
+1,441
+13% +$175K 0.3% 35
2021
Q1 		$1.37M Buy
+11,209
New +$1.69M 0.23% 46

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Koss-Olinger Consulting's CRSP Position: Q1 2026 in Review

Koss-Olinger Consulting sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 11,447 shares — an estimated $600K sold.

Koss-Olinger Consulting first reported a position in CRSP in Q1 2021 and held it in 13 quarters. The position peaked at $2.05M in Q2 2025. 491 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Koss-Olinger Consulting reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Koss-Olinger Consulting sold 11,447 CRISPR Therapeutics shares in Q1 2026, an estimated $600K.
  • Koss-Olinger Consulting first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 13 quarters.
  • Koss-Olinger Consulting's CRISPR Therapeutics position peaked at $2.05M in Q2 2025.
  • 491 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Koss-Olinger Consulting's 13F filing for Q1 2026, filed 7 May 2026.